UBS Global Biopharma Conference 2026
Logotype for Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals (VRTX) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Vertex Pharmaceuticals Inc

UBS Global Biopharma Conference 2026 summary

16 Nov, 2026

Business and milestones

  • Q3 results showed balanced CF growth in the U.S. and internationally; JOURNAVX and CASGEVY remained on track to contribute more than $500 million in 2026 against revenue guidance above $13 billion.

  • Key upcoming milestones include the Nov. 30, 2026 PDUFA date for povetacicept in IgAN and phase II proof-of-concept results in myotonic dystrophy type 1 before year-end 2026.

  • The portfolio now spans CF, sickle cell disease, acute pain and acromegaly, with IgAN planned as the first renal launch.

Renal pipeline and IgAN launch

  • Povetacicept is launch-ready, with FDA review events proceeding on track for the Nov. 30, 2026 PDUFA date.

  • At 36 weeks, data showed >50% proteinuria reduction, >80% hematuria resolution and >40% of patients meeting KDIGO guidelines; no head-to-head comparisons were available.

  • Monthly at-home auto-injector dosing uses a 0.46 mL dose with lower viscosity than peers; serious infection rates were 0.5% in both the placebo and povetacicept arms.

  • Expected monitoring and labeling are consistent with peers; the trial checked IgG monthly, while cross-trial monitoring differences limit direct comparisons.

  • The U.S. has 160,000 biopsy-confirmed diagnosed IgAN patients; more than 90% of the trained sales force has prior nephrology experience, with payer discussions and patient support preparations underway.

  • Inaxaplin AMPLITUDE interim analysis is expected in Q1 2027; the 48-week eGFR-slope result could support a U.S. accelerated-approval path if positive.

  • In APOL1-mediated kidney disease, earlier studies showed proteinuria reductions in the mid-to-high 40% range; the potential U.S. population is ~150,000, expanding to ~250,000 with comorbidities such as type 2 diabetes.

  • Most potential APOL1-mediated kidney disease patients are undiagnosed; a companion diagnostic and genetic testing outreach are anticipated to support a precision-medicine launch.

Pain franchise

  • Two phase III diabetic peripheral neuropathy studies are on track to complete enrollment by year-end 2026, with results expected by mid-2027; both are 12-week, placebo-controlled studies, and one includes pregabalin as a comparator.

  • The phase II study showed a two-point NPRS reduction; phase III success will depend substantially on managing the placebo effect.

  • A NaV1.7 program remains late preclinical; entry into clinical testing is hoped for in 2027, likely directly in combination with NaV1.8 inhibition.

  • JOURNAVX prescriptions are on track to more than triple in 2026 vs. 2025; Q3 revenue was slightly above flat sequentially as reimbursement conversion remained a constraint.

  • Free-drug patient support is planned to continue through mid-2027 and then phase out gradually; gross-to-net is expected to normalize to the mid-50% range by mid-2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Vertex Pharmaceuticals